Novo Nordisk A/S

Eli Lilly and Company

Over the past year - from July 2024 to August 2025 - Novo Nordisk's stock, <a href="https://oninvest.com/issuers/novo-b-co">has lost</a> nearly 70% in value. That's a fantastic collapse for a company that makes sought-after diabetes and weight-loss drugs&nbsp; and is showing good revenue and profit growth. What happened to Novo Nordisk and how much of this investor reaction is justified?

Matthew Whitehouse

Writes about:

Eli Lilly and Company

Novo Nordisk A/S

Articles: 1

The Novo Nordisk case: how the creator of Ozempic lost leadership in the market it created